SEC Filing Summary: BioDrain Medical, Inc. (10-Q)
Business Context and Reporting Period
Company: BioDrain Medical, Inc. (Note: Request metadata listed "Axe Compute Inc.", but the filing text identifies the registrant as BioDrain Medical, Inc.)
Period: Quarterly report for the period ended June 30, 2010.
Status: Development stage company. The company is developing an environmentally safe system for the collection and disposal of infectious fluids from surgical procedures (Fluid Management System or "FMS").
Going Concern: The filing states that recurring losses and a shareholders' deficit raise substantial doubt about the company's ability to continue as a going concern. Management is actively seeking $3-$5 million in new equity to fund operations for the next 12 months.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenue | $288 | $15,737 |
| Net Loss | $(798,070) | $(1,742,425) |
| Cash Balance (End of Period) | $8,834 | $235,227 |
| Net Cash Used in Operating Activities | $(538,498) | $(706,894) |
| Total Assets | $204,315 | $290,295 |
| Total Liabilities | $2,212,835 | $2,632,326 |
| Shareholders' Deficit | $(2,008,521) | $(2,342,031) |
| Accumulated Deficit | $(6,827,438) | $(6,029,368) |
Debt and Liquidity: The company holds approximately $390,000 in long-term debt (net of discounts) and $13,620 in current debt. Accounts payable increased to $1,034,598. Cash on hand is critically low at $8,834.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $288 from $15,737 in the prior year period. The company recorded no revenue in the three months ended June 30, 2010. The prior year revenue was from a single initial order in June 2009.
- Net Loss Improvement: Net loss decreased significantly to $798,070 from $1,742,425. This improvement is largely non-cash, driven by a $676,414 gain on the revaluation of equity-linked financial instruments (warrants), compared to a $436,423 loss in the prior period.
- Expense Fluctuations: General and Administrative (G&A) expenses increased to $1.15 million (from $872k) due to a $527,000 increase in stock-based consulting expenses for fundraising. However, this was offset by a $319,000 decrease in stock-based registration payment expenses incurred in 2009.
- Interest Expense: Interest expense increased to $73,707 from $39,320 due to amortization of debt discounts on new convertible debt.
Guidance, Outlook, and Risks
- Capital Needs: Management estimates a need for approximately $3 million to fund operations for the next 12 months. An investment banker was hired in February 2010 to raise $3-$5 million. As of June 30, 2010, the company had raised approximately $175,000 in 2010 but failed to meet an interim target of $500,000.
- Operational Outlook: The company received FDA 510(k) clearance on April 1, 2009. Operations are currently limited by the inability to pay contract manufacturers to produce and ship units. Revenue is expected to increase only after sufficient financing is secured.
- Legal Contingency: A lawsuit filed by a former officer (Gerald Rice) regarding unpaid wages was settled in July 2010 (subsequent to the period end). The settlement requires the company to pay $130,000 over several months, contingent on the company raising a minimum of $500,000.
- Risk Factors: Substantial doubt exists regarding the company's ability to continue as a going concern. Failure to raise additional capital could force the company to reduce expenditures or cease operations. Future equity financing will likely result in significant shareholder dilution.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and the timeline for the anticipated $3-$5 million equity raise, given the filing states cash may only last through Q3 2010.
- Settlement Obligations: Confirm the status of the $130,000 settlement with the former officer and whether the $500,000 fundraising trigger for payments has been met.
- Debt Conversion Terms: Review the terms of the convertible debt issued in 2010 (including the $200,000 note to an officer's parents) to understand potential dilution upon conversion.
- Revenue Pipeline: Assess the status of contracts with independent sales representatives and the ability to fund contract manufacturing for the FMS units.
- Equity-Liability Valuation: Understand the volatility of the "Gain on valuation of equity-linked instruments" line item, which significantly masks the operating cash burn.